More importantly, we revealed for the first time that promoting IL-10 production and the CD4+IL-10+ T cells may be a novel mechanism involved in the amelioration of EAE exhibited by CD226 ligation, thus indicating that blocking CD226 molecule may be a novel target for the therapeutic intervention and treatment of MS by enhancing the expression of IL-10 and iTreg differentiation. This evidence concerns the gene CD4 and myeloid sarcoma.